| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/14/2010 | WO2010004390A1 Quinazoline dione derivatives as trpa1 modulators |
| 01/14/2010 | WO2010004386A2 Amorphous bupropion hydrobromide and preparation thereof |
| 01/14/2010 | WO2010004385A1 Process for the preparation of pure 4'-[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid |
| 01/14/2010 | WO2010004348A1 Heterocyclic gpcr agonists |
| 01/14/2010 | WO2010004347A1 Heterocyclic gpcr agonists |
| 01/14/2010 | WO2010004346A1 Piperidinyl gpcr agonists |
| 01/14/2010 | WO2010004345A1 Piperidinyl gpcr agonists |
| 01/14/2010 | WO2010004344A1 Piperidine gpcr agonists |
| 01/14/2010 | WO2010004343A1 Piperidinyl gpcr agonists |
| 01/14/2010 | WO2010004339A1 Processes for the preparation of crystalline forms of sunitinib malate |
| 01/14/2010 | WO2010004337A1 Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed |
| 01/14/2010 | WO2010004319A1 Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt |
| 01/14/2010 | WO2010004304A1 Novel compounds and methods for their production |
| 01/14/2010 | WO2010004303A1 Compositions for the treatment of hair loss |
| 01/14/2010 | WO2010004283A2 Therapy |
| 01/14/2010 | WO2010004256A1 Controlled release treatment of depression |
| 01/14/2010 | WO2010004231A2 Novel compounds, use thereof as medicaments, and method for the preparation thereof |
| 01/14/2010 | WO2010004221A2 Use of indole derivatives as nurr-1 activators for treating parkinson’s disease |
| 01/14/2010 | WO2010004215A2 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof |
| 01/14/2010 | WO2010004198A2 Antineoplastic derivatives, preparation thereof, and therapeutic use thereof |
| 01/14/2010 | WO2010004197A2 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof |
| 01/14/2010 | WO2010004139A1 New cycloalkylated benzothiadiazine derivatives, method for preparing them and pharmaceutical compositions containing them |
| 01/14/2010 | WO2010004060A1 Use of cilastatin for reducing nephrotoxicity of different compounds |
| 01/14/2010 | WO2010004051A1 Antagonists of nr2f6 for augmenting the immune response |
| 01/14/2010 | WO2010004022A1 Directly pressed aliskiren tablets |
| 01/14/2010 | WO2010004016A1 Use of phenoxyalkylamines in cosmetic and/or dermatological compositions |
| 01/14/2010 | WO2010004005A1 Compositions that aim to promote the development and growth of a beneficial vaginal microflora |
| 01/14/2010 | WO2010003996A1 Eprosartan compositions |
| 01/14/2010 | WO2010003992A1 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 01/14/2010 | WO2010003976A1 Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors |
| 01/14/2010 | WO2010003963A1 Use of opioid antagonists for treating urinary retention |
| 01/14/2010 | WO2010003803A1 Nutritional composition containing oligosaccharide mixture |
| 01/14/2010 | WO2010003797A1 Hyaluronic acid for corneal wound healing |
| 01/14/2010 | WO2010003760A2 Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity |
| 01/14/2010 | WO2010003700A1 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer |
| 01/14/2010 | WO2010003658A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
| 01/14/2010 | WO2010003641A1 Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| 01/14/2010 | WO2010003624A2 Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| 01/14/2010 | WO2010003601A1 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use |
| 01/14/2010 | WO2010003568A1 Topical composition for the treatment of actinic keratosis |
| 01/14/2010 | WO2010003528A1 Medicament comprising dimethyl fumarate for treating an illness caused by parasites |
| 01/14/2010 | WO2010003465A2 A drug powder for inhalation administration and a process thereof |
| 01/14/2010 | WO2010003376A1 Methods for treatment and/or prevention of cancer with andrographolide (and) and use thereof |
| 01/14/2010 | WO2010003369A1 Cyclin-dependent kinases inhibitor of baicalin organic amine derivatives, synthesis and use thereof |
| 01/14/2010 | WO2010003319A1 Hydrates of erythromycin salts, the preparation and the use thereof |
| 01/14/2010 | WO2010003313A1 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| 01/14/2010 | WO2010003308A1 The use of nitric oxide and signal transduction system thereof in preparing medicaments for targeted therapy of malignant tumors |
| 01/14/2010 | WO2010003295A1 Use of ginsenoside rb1 in preparing medicaments for treating dilated cardiomyopathy |
| 01/14/2010 | WO2010003287A1 THE USE OF POTASSIUM 2-(α- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA |
| 01/14/2010 | WO2010003279A2 A cryosurgery anticancer antigen preparation and its preparation method |
| 01/14/2010 | WO2010003238A1 Phase 2 protein inducing alkamides |
| 01/14/2010 | WO2010003232A1 Treating cancer using atractyloside |
| 01/14/2010 | WO2010003197A1 Morpholine derivatives used as antifungal compounds |
| 01/14/2010 | WO2010003178A1 A synthetic vaccine component |
| 01/14/2010 | WO2009144551A3 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood |
| 01/14/2010 | WO2009143463A3 Methods for modulating expression of creb |
| 01/14/2010 | WO2009143371A3 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF |
| 01/14/2010 | WO2009143224A3 Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research |
| 01/14/2010 | WO2009143181A3 Micro-rna profile in human saliva and its use for detection of oral cancer |
| 01/14/2010 | WO2009143156A3 Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators |
| 01/14/2010 | WO2009142771A3 Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan |
| 01/14/2010 | WO2009141827A3 A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions |
| 01/14/2010 | WO2009140205A3 Therapeutic substituted cyclopentanes |
| 01/14/2010 | WO2009138186A3 SEQUENTIAL ADMINISTRATION OF 20,20,21,21-PENTAFLUORO-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIENE-3-ONE AND ONE OR MORE PROGESTATIONAL HORMONES FOR TREATING GYNAECOLOGICAL DISEASES |
| 01/14/2010 | WO2009137533A3 Ameliorating nervous systems disorders |
| 01/14/2010 | WO2009137251A3 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
| 01/14/2010 | WO2009132453A8 Cyclylamine derivatives as calcium channel blockers |
| 01/14/2010 | WO2009132050A3 Auris formulations for treating otic diseases and conditions |
| 01/14/2010 | WO2009130616A3 Improved tlr3 agonist compositions |
| 01/14/2010 | WO2009129145A3 Sulfasalazine formulations in a biodegradable polymer carrier |
| 01/14/2010 | WO2009128917A3 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 01/14/2010 | WO2009126866A3 Delta-tocotrienol as a radioprotective countermeasure agent |
| 01/14/2010 | WO2009126861A3 Triazolopyridine compounds useful as dgat1 inhibitors |
| 01/14/2010 | WO2009126737A3 Triterpene saponins, methods of synthesis, and uses thereof |
| 01/14/2010 | WO2009126551A3 Bis-aromatic anticancer agents |
| 01/14/2010 | WO2009126530A3 Piperidine derivatives as cgrp receptor antagonists |
| 01/14/2010 | WO2009126335A3 Ant2 inhibitor compounds and methods of use thereof |
| 01/14/2010 | WO2009124103A3 Combination therapies comprising par1 antagonists with par4 antagonists |
| 01/14/2010 | WO2009121872A3 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| 01/14/2010 | WO2009121018A4 Opioid-nornicotine codrugs for pain management |
| 01/14/2010 | WO2009120371A3 Computationally designed inhibitors of amyloidosis |
| 01/14/2010 | WO2009118706A9 The treatment of helminthic infections |
| 01/14/2010 | WO2009118589A3 Orally disintegrating compositions of rhein or diacerein |
| 01/14/2010 | WO2009117150A3 Method of treating lupus with ceramide derivatives |
| 01/14/2010 | WO2009114725A3 Mobilization op hematopoietic stem cells using cdc42 inhibitors |
| 01/14/2010 | WO2009109973A3 Compounds and methods of treating obesity |
| 01/14/2010 | WO2009108857A3 Combination therapy for prostate cancer |
| 01/14/2010 | WO2009104100A3 Antibody combinations, and methods of making and using same |
| 01/14/2010 | WO2009099650A4 Treatment of bladder diseases with a tlr7 activator |
| 01/14/2010 | WO2009098490A4 Antimicrobial agents for the treatment of campylobacter species in the crop of a bird |
| 01/14/2010 | WO2009098464A3 Use of g-rich oligonucleotides for treating neoplastic diseases |
| 01/14/2010 | WO2009094560A3 Thienopyranones as kinase inhibitors |
| 01/14/2010 | WO2009094205A3 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 01/14/2010 | WO2009089494A3 Pharmaceutical compositions |
| 01/14/2010 | WO2009085832A3 Manufacture of tablet |
| 01/14/2010 | WO2009080821A3 Multitarget compounds active at a ppar and cannabinoid receptor |
| 01/14/2010 | WO2009052090A3 Silicate containing compositions and methods of treatment |
| 01/14/2010 | WO2009044380A3 Formulations containing orlistat particles having controlled particle size |
| 01/14/2010 | WO2008134628A3 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| 01/14/2010 | WO2005041874A9 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells |